Target intelligence / Profile preview

5-hydroxytryptamine 3A receptor (5-HT₃A receptor)

Target
5-HT₃A receptor
Molecular classification
Ion channel, Ligand-gated ion channel, Cys-loop receptor, Pentameric ligand-gated ion channel (pLGIC), Receptor
01

Overview

The **5-hydroxytryptamine 3A receptor** (5-HT₃A receptor) is a serotonin-gated ligand-gated ion channel, part of the Cys-loop superfamily, responsible for fast excitatory synaptic transmission in the central and peripheral nervous system. Unlike most serotonin receptors (which are G protein-coupled), the 5-HT₃A receptor forms a homopentameric or heteropentameric cation channel permeable to Na⁺ and K⁺ ions. Its activation by serotonin (5-hydroxytryptamine, 5-HT) causes neuronal depolarization, playing essential roles in processes like neurotransmission, emesis (vomiting), pain modulation, cognition, and gastrointestinal motility. The 5-HT₃A receptor is a major clinical target, with its antagonists ("setrons") used primarily as antiemetic agents during chemotherapy, radiotherapy, and surgery, and under study for use in neuropsychiatric and gastrointestinal disorders. Receptor dysfunction or polymorphisms are implicated in a variety of neuropsychiatric, pain, and digestive system disorders.

Other names
5-HT3A receptorSerotonin receptor 3AHTR3A5-HT3 receptor (specifically the A subunit or homopentameric form)Serotonin-gated ion channel
02

Mechanism of action

Competitive antagonism at the serotonin binding site; Inhibition of receptor-gated cation influx (Na⁺, K⁺); Inhibition of neuronal depolarization and neurotransmitter release; Allosteric modulation in some cases

03

Biological functions

Fast synaptic transmissionSignal transductionNeuronal excitationNeurotransmitter releaseModulation of synaptic plasticity and neurogenesis
04

Disease associations

Neuropsychiatric disordersNausea and vomiting (Chemotherapy-induced, postoperative)Irritable bowel syndromePain disordersDepressionAnxietySchizophreniaNeurodegenerative diseaseInflammationOther gastrointestinal disorders
05

Safety considerations

QT prolongation and risk of cardiac arrhythmia for some antagonists (e.g. dolasetron)HeadacheConstipationRarely, serotonin syndrome if combined with serotonergic agentsLimited CNS penetration for some agents may affect efficacy
06

Interacting drugs

Ondansetron

6 more in the full profile.

07

Biomarkers

HTR3A gene polymorphisms (may influence drug response or receptor function)

Beyond the preview

Go deeper on 5-hydroxytryptamine 3A receptor (5-HT₃A receptor).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-hydroxytryptamine 3A receptor (5-HT₃A receptor).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call